Errors in Analysis of Study of Photocoagulation vs Ranibizumab for Diabetic Retinopathy

No authors listed

Published Erratum

No authors listed. JAMA. 2019.

. 2019 Mar 12;321(10):1008.

doi: 10.1001/jama.2019.0265.

No abstract available

Erratum for

Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial.
Writing Committee for the Diabetic Retinopathy Clinical Research Network; Gross JG, Glassman AR, Jampol LM, Inusah S, Aiello LP, Antoszyk AN, Baker CW, Berger BB, Bressler NM, Browning D, Elman MJ, Ferris FL 3rd, Friedman SM, Marcus DM, Melia M, Stockdale CR, Sun JK, Beck RW. Writing Committee for the Diabetic Retinopathy Clinical Research Network, et al. JAMA. 2015 Nov 24;314(20):2137-2146. doi: 10.1001/jama.2015.15217. JAMA. 2015. PMID: 26565927 Free PMC article. Clinical Trial.

1. Gross JG, Glassman AR, Jampol LM, et al. ; Writing Committee for the Diabetic Retinopathy Clinical Research Network . Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial. JAMA. 2015;314(20):2137-2146. doi:10.1001/jama.2015.15217 - DOI - PMC - PubMed
1. Glassman AR. Errors in analysis of mean deviations in study of photocoagulation vs ranibizumab for diabetic retinopathy [published March 12, 2019]. JAMA. doi:10.1001/jama.2019.0374 - DOI - PubMed
1. Coordinating clinical site omitted. JAMA. 2016;315(9):944. doi:10.1001/jama.2016.1591 - DOI - PubMed